Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up

BJU Int. 2019 Jan;123(1):58-64. doi: 10.1111/bju.14393. Epub 2018 Jun 7.

Abstract

Objectives: To determine the outcomes of complete surgical resection of T4 prostate cancer after inductive androgen-deprivation therapy (ADT), as inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet.

Patients and methods: A monocentric RP database was queried for patients initially diagnosed with T4 prostate cancer, considered primarily as inoperable because of a fixed mass defined by rectal examination in combination with high PSA level and/or large foci of biopsy confirmed undifferentiated prostate cancer. Treatment consisted of primary ADT until PSA nadir with consecutive RP. Patients underwent retropubic RP (RRP) or robot-assisted laparoscopic RP (RALP) after inductive ADT until achievement of the PSA nadir, which is in general reached after 6-7 months. The intraoperative course and complications were analysed. Finally, Kaplan-Meier estimates were calculated for overall survival (OS) and prostate cancer-specific survival (PCSS).

Results: We retrospectively identified 116 patients treated between 2000 and 2014. At diagnosis, the median (range) PSA level was 37.6 (2.44-284) ng/mL. The preoperative median (range) PSA after inductive ADT was 0.73 (0.01-34) ng/mL. Thereafter, patients underwent RRP or, since 2006, RALP. The median (95% confidence interval) OS was 156 (118.9-193.1) months. The PCSS at 150 months was 82%.

Conclusions: Surgical therapy of primarily inoperable prostate cancer is feasible and safe after inductive ADT. The OS of this cohort seems comparable with results described for patients with primary operable high-risk prostate cancer.

Keywords: #ProstateCancer; #pcsm; inductive androgen deprivation; inoperable high-risk prostate cancer; prostate-specific antigen nadir; radical prostatectomy.

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Chemotherapy, Adjuvant
  • Follow-Up Studies
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Induction Chemotherapy
  • Intestinal Perforation / etiology*
  • Intraoperative Complications / etiology
  • Kaplan-Meier Estimate
  • Lymphocele / etiology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Postoperative Complications / etiology
  • Prostate-Specific Antigen / blood*
  • Prostatectomy / methods*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Rectum / injuries*
  • Retrospective Studies
  • Survival Rate
  • Time Factors
  • Urinary Bladder Neck Obstruction / etiology

Substances

  • Androgen Antagonists
  • Gonadotropin-Releasing Hormone
  • Prostate-Specific Antigen